Home›Trial›NCT05776225
NCT05776225RECRUITING

Pulmonary Hypertension Screening in Patients With Interstitial Lung Disease for Earlier Detection

Study Summary

Study GMS-PH-001 is a multicenter, open-label, non-randomized study to prospectively evaluate screening strategies of pulmonary hypertension (PH) in patients with interstitial lung disease (ILD).

Conditions
Interstitial Lung DiseasePulmonary Hypertension
Interventions / Drugs
Right heart catheterization (RHC)
View on ClinicalTrials.gov ↗
Sponsor
UTHR
United Therapeutics
Pulmonary
D35/100
Study Details
Enrollment300 participants
Primary Completion—
Lead SponsorUnited Therapeutics
Data Retrieved2026-04-11 04:30:42.432949+00:00
What This Trial Means for Biotech Investors
Trial Phase Context
Status & Expected Data

Currently recruiting: the trial is enrolling patients. A data readout is not expected until after enrollment closes and the follow-up period is complete.

Enrolled: 300 participants
Sponsor Catalyst Profile

United Therapeutics (UTHR) is the sponsoring company for this trial. BiotechSign currently grades this company D (35/100) based on composite catalyst signals across its full pipeline. This trial is one data point in that overall catalyst picture.

UTHR Full Pipeline →All Companies →
Not financial advice. BiotechSign data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.